The COVID-19 pandemic has tremendously affected human lives. Although its panic is slowly diminishing with adequate precaution, the cases of infected patients have not curbed. The World Health Organization, has termed the novel Coronavirus as an infectious disease with symptoms, such as mild to moderate respiratory illness. Besides, the geriatric population and people with underlying medical complications, such as chronic respiratory disease, diabetes, cardiovascular disease, cancer, are prone to develop severe illness. Hence, in order to provide respiratory support, extracorporeal membrane oxygenation (ECMO) systems have witnessed significant demand globally. These systems substitute the capacity of the lungs and heart to deliver oxygen or dispose of carbon dioxide from the body.

The global extracorporeal membrane oxygenation (ECMO) system market is surging at a rapid pace due to the rising respiratory diseases and providing support to severely affected COVID-19 patients. There has been a significant increase in the usage of ECMO support in the healthcare systems during the pandemic. Moreover, the US FDA has issued guidance to grow the accessibility of devices utilized in extracorporeal Membrane oxygenation (ECMO) treatment to address the public health emergency.

Below are few companies actively operating in the ECMO systems market:

Abbott Laboratories

Abbott Laboratories operates through segments such as, diagnostics, pharmaceuticals, cardiovascular, nutritionals, and neuromodulation, and others. The other segment includes medical optics products. The company aims to spend on R&D in six platforms spanning across adult, pediatric, and performance nutrition areas. In April 2020, the company’s CentriMag Circulatory Support System received FDA clearance for the cardiopulmonary bypass. The CentriMag system is capable of being used in a cardiopulmonary bypass circuit for Extracorporeal Membrane Oxygenation (ECMO) therapy.

Medtronic PLC

Medtronic PLC sells and manufactures device-based on medical therapies. It operates through four segments, namely, the minimally invasive therapies group, cardiac and vascular group, restorative therapies group, and diabetes group. The vascular and cardiac segment includes the cardiac rhythm and heart failure, peripheral vascular, and aortic divisions. The Nautilus Smart ECMO Module by the company recovers long-term gas transfer while giving ongoing device execution information available from an instinctive touch screen.

Getinge AB

Getinge AB is a medical technology company, which delivers systems, equipment, operating rooms, and intensive care units to the life science and healthcare industries. It operates through three major businesses, viz. patient and post-acute care, acute care therapies, and surgical workflows. The acute care therapies segment offers resolutions for life support in health conditions, including pulmonary, cardiac, and vascular therapies.

Getinge has an expansive, top of the line product portfolio for short term or delayed extracorporeal membrane oxygenation (ECMO) or extracorporeal life support (ECLS). It includes a selection of consumables and gadgets to give adequate extracorporeal heart and lung support to an individual. For example, oxygenators, tubing sets, centrifugal pumps, warmer units, and catheters and cannulae.

Terumo Corporation

The company has three major business segments, namely vascular and cardiac company, which is specialized in endovascular intervention and cardiovascular surgery. Another segment is the general hospital company, which is focused on the purchase, manufacture, and sales of pharmaceuticals, hospital medical equipment, diabetes-related products, peritoneal dialysis equipment, home medical products, and the rental of hospital medical equipment. Terumo provides lifesaving and life-supporting products so that healthcare specialists can continue to aid their patients worldwide. These include hardware used to treat COVID-19 patients, such as apheresis systems and ECMO, to medical products vital for regular clinical practice.

Thus, with the existing designated ECMO centers being supportive of the development of new centers, the global ECMO system market looks promising in the upcoming years.